{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:28:02Z","timestamp":1795080482853,"version":"4.10.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas\/neuroendocrine tumors (NEC\/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I\/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC\/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC\/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3\u2009mg\/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3\/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15\/145 patients (10%) treated at 0.3\u2009mg\/kg, including 9\/69 patients (13%) with NEC\/NET. Rova-T at 0.3\u2009mg\/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC\/NET, melanoma, MTC, and glioblastoma.<\/jats:p>","DOI":"10.1038\/s41698-021-00214-y","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:02:50Z","timestamp":1628143370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["A phase I\/II study of rovalpituzumab tesirine in delta-like 3\u2014expressing advanced solid tumors"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna F.","family":"Farago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-2226","authenticated-orcid":false,"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiama N.","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Hendifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell B.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-3895","authenticated-orcid":false,"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-8587","authenticated-orcid":false,"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrianne","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-7982","authenticated-orcid":false,"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"214_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/hmg\/ddq529","volume":"20","author":"G Chapman","year":"2011","unstructured":"Chapman, G., Sparrow, D. B., Kremmer, E. & Dunwoodie, S. L. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum. Mol. Genet. 20, 905\u2013916 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"214_CR2","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7, 302ra136 (2015).","journal-title":"Sci. Transl. Med."},{"key":"214_CR3","doi-asserted-by":"publisher","unstructured":"von Arx, C. et al. Updates on the role of molecular alterations and NOTCH signalling in the development of neuroendocrine neoplasms. J. Clin. Med. 8, https:\/\/doi.org\/10.3390\/jcm8091277 (2019).","DOI":"10.3390\/jcm8091277"},{"key":"214_CR4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360\u2013364 (2017).","journal-title":"Nature"},{"key":"214_CR5","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1242\/dev.124.16.3065","volume":"124","author":"SL Dunwoodie","year":"1997","unstructured":"Dunwoodie, S. L., Henrique, D., Harrison, S. M. & Beddington, R. S. Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 124, 3065\u20133076 (1997).","journal-title":"Development"},{"key":"214_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.lungcan.2019.10.010","volume":"138","author":"BCM Hermans","year":"2019","unstructured":"Hermans, B. C. M. et al. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. Lung Cancer 138, 102\u2013108 (2019).","journal-title":"Lung Cancer"},{"key":"214_CR7","doi-asserted-by":"publisher","unstructured":"Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aav0891 (2019).","DOI":"10.1126\/scitranslmed.aav0891"},{"key":"214_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cncr.32750","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study. Cancer 126, 2086\u20132092 (2020).","journal-title":"Cancer"},{"key":"214_CR9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/cas.12473","volume":"105","author":"T Yamaguchi","year":"2014","unstructured":"Yamaguchi, T. et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105, 1176\u20131181 (2014).","journal-title":"Cancer Sci."},{"key":"214_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry, E. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer 81, 1351\u20131355 (1999).","journal-title":"Br. J. Cancer"},{"key":"214_CR11","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1200\/JCO.2005.05.0575","volume":"24","author":"JD Hainsworth","year":"2006","unstructured":"Hainsworth, J. D., Spigel, D. R., Litchy, S. & Greco, F. A. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J. Clin. Oncol. 24, 3548\u20133554 (2006).","journal-title":"J. Clin. Oncol."},{"key":"214_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye, H. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24, 152\u2013160 (2013).","journal-title":"Ann. Oncol."},{"key":"214_CR13","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1002\/cncr.26124","volume":"117","author":"S Welin","year":"2011","unstructured":"Welin, S. et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117, 4617\u20134622 (2011).","journal-title":"Cancer"},{"key":"214_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1078-0432.CCR-18-2312","volume":"25","author":"M Spino","year":"2019","unstructured":"Spino, M. et al. Cell surface notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma. Clin. Cancer Res. 25, 1261\u20131271 (2019).","journal-title":"Clin. Cancer Res."},{"key":"214_CR15","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer, R. et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v126\u2013v132 (2015).","journal-title":"Ann. Oncol."},{"key":"214_CR16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"214_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","volume":"161","author":"RW Randle","year":"2017","unstructured":"Randle, R. W. et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 161, 137\u2013146 (2017).","journal-title":"Surgery"},{"key":"214_CR18","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","volume":"15","author":"QT Ostrom","year":"2013","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro. Oncol. 15, ii1\u2013ii56 (2013).","journal-title":"Neuro. Oncol."},{"key":"214_CR19","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","volume":"25","author":"R Stupp","year":"2014","unstructured":"Stupp, R. et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii93\u2013iii101 (2014).","journal-title":"Ann. Oncol."},{"key":"214_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 18, 42\u201351 (2017).","journal-title":"Lancet Oncol."},{"key":"214_CR21","doi-asserted-by":"publisher","unstructured":"Morgensztern, D. et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin. Cancer Res., https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1133 (2019).","DOI":"10.1158\/1078-0432.CCR-19-1133"},{"key":"214_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","volume":"17","author":"ML Miller","year":"2018","unstructured":"Miller, M. L. et al. A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody-drug conjugates (ADCs). Mol. Cancer Ther. 17, 650\u2013660 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"214_CR23","doi-asserted-by":"publisher","unstructured":"Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody-drug conjugates: the last decade. Pharmaceuticals 13, https:\/\/doi.org\/10.3390\/ph13090245 (2020).","DOI":"10.3390\/ph13090245"},{"key":"214_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","volume":"23","author":"E Khera","year":"2021","unstructured":"Khera, E. et al. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia 23, 210\u2013221 (2021).","journal-title":"Neoplasia"},{"key":"214_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2217\/cns.14.55","volume":"4","author":"C Kam Kamiya-Matsuoka","year":"2015","unstructured":"Kam Kamiya-Matsuoka, C. & Gilbert, M. R. Treating recurrent glioblastoma: an update. CNS Oncol. 4, 91\u2013104 (2015).","journal-title":"CNS Oncol."},{"key":"214_CR26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/cas.14015","volume":"110","author":"N Yamazaki","year":"2019","unstructured":"Yamazaki, N. et al. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. Cancer Sci. 110, 1995\u20132003 (2019).","journal-title":"Cancer Sci."},{"key":"214_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr.","year":"2015","unstructured":"Wells, S. A. Jr. et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567\u2013610 (2015).","journal-title":"Thyroid"},{"key":"214_CR28","doi-asserted-by":"publisher","unstructured":"Okuyama, H. et al. A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology, https:\/\/doi.org\/10.1159\/000505550 (2020).","DOI":"10.1159\/000505550"},{"key":"214_CR29","doi-asserted-by":"publisher","unstructured":"Sugiyama, K. et al. Salvage chemotherapy by FOLFIRI regimen for poorly differentiated gastrointestinal neuroendocrine carcinoma. J Gastrointest. Canc., https:\/\/doi.org\/10.1007\/s12029-020-00516-7 (2020).","DOI":"10.1007\/s12029-020-00516-7"},{"key":"214_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"214_CR31","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","volume":"25","author":"JR Eckardt","year":"2007","unstructured":"Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086\u20132092 (2007).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00214-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:53:48Z","timestamp":1670075628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1038\/s41698-021-00214-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.M. reports honoraria to institution from AbbVie, AstraZeneca, Bristol Myers Squibb, and Genentech; research funding from the National Institutes of Health, Novartis, and Verily; nonremunerated director of Mesothelioma Applied Research Foundation. D.S.H. reports a leadership role or other ownership with OncoResponse, Molecular Match, and Presagia Inc.; a consultancy\/advisory role for Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza Therapeutics, and WebMD; travel support from Bayer, Loxo, miRNA, Genmab, AACR, ASCO, and SITC; research funding from AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Eli Lilly, Loxo Oncology, Merck, MedImmune, Mirati Therapeutics, miRNA, Molecular Templates, MOLOGEN AG, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, and Turning Point Therapeutics. C.L.H. reports a consultancy\/advisory role with AbbVie, Ascentage Pharma, Bristol Myers Squibb, and Genentech; research funding to institution from AbbVie, Amgen, AstraZeneca, and Bristol Myers Squibb. A.F.F. reports a consultancy\/advisory role with Bayer, Loxo Oncology, Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar, Boehringer Ingelheim, Merck, H3 Biomedicine, and Pfizer; research funding from Bayer, Loxo Oncology, Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar, Merck, Ignyta, Amgen, and Novartis; honoraria from DAVA Oncology, Clinical Care Options, Medical Learning Institute, Medscape, PeerView, and Research to Practice. H.B. reports a consultancy\/advisory role with Janssen, Sanofi Genzyme, Pfizer, Astellas, AstraZeneca, and Merck; research funding from AbbVie\/Stemcentrx; research funding to institution from Janssen Oncology, Eli Lilly, and Millennium Pharmaceuticals. S.N.W. reports research funding to institution from Spectrum Pharmaceuticals, Eli Lilly, Pfizer, Roche\/Genentech, Daiichi Sankyo, NewLink Genetics, EMD Serono, Puma Biotechnology, Novartis, Xcovery, Synermore Biologics, Celgene, Vertex, Bristol Myers Squibb, Stemcentrx, Hengrui Therapeutics, Checkpoint Therapeutics, Ignyta, AstraZeneca, ARIAD, Roche, and Merck. A.E.H. reports a consultancy\/advisory role with Novartis, Ipsen, Perthera, Celgene, and AbbVie; research funding from AbbVie; travel accommodations from Halozyme. L.B.A. reports a consultancy\/advisory role for Lexicon; research funding to institution from AbbVie, Oncotelic, and Entrinsic Health Solutions. M.H.T. reports a consultancy\/advisory role with and honoraria from Bristol Myers Squibb, Eisai, Novartis, Bayer, Sanofi\/Genzyme, Array Biopharma, Loxo Oncology, Blueprint Medicines, and Arqule; speakers\u2019 bureau for and honoraria from Bristol Myers Squibb and Eisai. A.H.B. reports honoraria from Astellas Pharma and Bayer; travel support from Clovis Oncology. S.T.T. reports a consultancy\/advisory role for Medivation, Astellas Pharma, Dendreon, Janssen, Bayer, Genentech, Endocyte, Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED Therapeutics, Amgen, Sanofi, Pfizer, Clovis Oncology, Novartis, and Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Aikido Pharma, Telix Pharma; travel support from Sanofi, Immunomedics, and Amgen; research funding to institution from Eli Lilly, Sanofi, Janssen, Astellas Pharma, Progenics, Millennium, Amgen, Bristol Myers Squibb, Dendreon, Rexahn Pharmaceuticals, Bayer, Genentech, NewLink Genetics, Inovio Pharmaceuticals, AstraZeneca, Immunomedics, Novartis, AVEO, Boehringer Ingelheim, Merck, Stemcentrx, Karyopharm Therapeutics, AbbVie, Medivation, Endocyte, Exelixis, Clovis Oncology, SeaGen, and Gilead. K.L. reports a consultancy\/advisory role for Array BioPharma, Merck, Roche, and Regeneron; honoraria from Array BioPharma; travel support from Merck, Roche\/Genentech, and Regeneron; research funding to the institution from Roche\/Genentech, Merck, Array BioPharma, Incyte, Nektar, Iovance Biotherapeutics, Bristol Myers Squibb, Kartos Therapeutics, OncoSec, Regeneron, Alkermes, and Neon Therapeutics; uncompensated relationship with Roche\/Genentech and Regeneron. J.N. reports a consultancy\/advisory role for Roche and Boehringer Ingelheim; honoraria from Onclive. C.H.C. reports a consultancy\/advisory role for Bristol Myers Squibb, Mirati, CUE Biopharma, Sanofi, and Ignyta; travel support from Bristol Myers Squibb; research funding from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Regeneron, Ignyta, Brooklyn Therapeutics, Pfizer, and lovance. J.M.C. reports research funding from Merck, AstraZeneca, Esperas Pharma, and Tesaro; a consultancy\/advisory role with Bristol Myers Squibb; travel funding from Bristol Myers Squibb. M.R. reports former employment by AbbVie, current employment with Calithera Biosciences, and may hold AbbVie stock. C.L., R.V., and Y.L. report employment by AbbVie and may own stock or other options. R.A. reports a consultancy\/advisory role for AstraZeneca and Janssen; honoraria from Clovis Oncology; travel support from Xynomic Pharmaceuticals; institution received research funding from Zenith Epigenetics, Novartis, Xynomic Pharmaceuticals, Cancer Targeted Technology, Janssen, Merck, and AbbVie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}